Published June 14, 2021
Buffalo Business First reports that UB spinoff company Garwood Medical Devices closed on a $4 million round of Series C funding to support the pre-clinical development of its BioPrax technology, which treats infections on metallic orthopaedic implants.
The article notes the company was founded in 2014 with technology licensed from UB and Syracuse University. Associate Professor Mark Ehrensberger, Department of Biomedical Engineering, was a co-inventor of the antimicrobial technology known as cathodic voltage-controlled electrical stimulation (CVCES), which led to the development of BioPrax.
